1 citations
,
April 2017 in “European Psychiatry” A patient's allergic reaction to clozapine resolved without stopping the medication, showing the importance of blood monitoring.
6 citations
,
January 2016 in “Pediatrics international” Japanese infants fed hydrolysate formula may have low biotin levels.
April 2018 in “Journal of Investigative Dermatology” Hydroxychloroquine may cause false results in tuberculosis tests for patients with autoimmune skin diseases.
The data suggests that dosing differences can help manage spasticity in patients with upper motor neuron dysfunction.
8 citations
,
May 2021 in “Reproductive Biology and Endocrinology” Different levels of anti-Müllerian hormone can help diagnose polycystic ovary syndrome in women of different ages.
May 2023 in “Frontiers in Endocrinology” Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.
November 2025 in “Skin Appendage Disorders” Immune cell-targeting biologics show potential for treating alopecia areata but need better-targeted therapies.
December 2025 in “PubMed” Baricitinib is effective and safe for treating severe alopecia areata.
December 2025 in “Cureus” Higher IL-17A and IL-23 levels are linked to alopecia areata severity and could help in tracking and treating the disease.
1 citations
,
April 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Tislelizumab can cause cutaneous lupus erythematosus.
1 citations
,
May 2021 in “Mayo Clinic Proceedings” A 69-year-old man with sinus infection and fainting spells was diagnosed with a rare kidney disease, treated with steroids and a specific drug, which improved his condition.
10 citations
,
August 2016 in “Oxford Medical Case Reports” Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.
December 2025 in “Naunyn-Schmiedeberg s Archives of Pharmacology” Agomelatine may help reduce benign prostatic hyperplasia by blocking certain inflammatory pathways.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
2 citations
,
September 2014 in “Nature reviews. Drug discover/Nature reviews. Drug discovery” Specific immune cells cause alopecia areata and blocking certain proteins can prevent it.
September 2019 in “Journal of Investigative Dermatology” Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
20 citations
,
July 2024 in “Archives of Dermatological Research” Dupilumab helps children with alopecia areata regrow hair safely.
July 2024 in “Journal of Investigative Dermatology” Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.
18 citations
,
March 1990 in “Archives of Dermatology” Cyclosporine cleared a woman's resistant skin condition quickly and kept it away for over a year.
13 citations
,
August 1997 in “Steroids” Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.
3 citations
,
July 2021 in “International journal of environmental research and public health/International journal of environmental research and public health” Two patients developed complete hair loss after Alemtuzumab treatment for MS, with no regrowth after two years.
January 2022 in “Menoufia Medical Journal /Menoufia Medical Journal” Higher levels of retinol-binding protein 4 are found in people with alopecia areata, but these levels don't relate to how severe the condition is.
4 citations
,
January 2019 in “Einstein (São Paulo)” Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.
August 2025 in “Intisari Sains Medis” The buffy coat method yields higher TGF-β1 levels in PRP, especially in males.
8 citations
,
April 2023 in “Dermatology Practical & Conceptual” Certain blood markers, especially MLR, can help diagnose alopecia areata.
March 2023 in “Indian Journal of Rheumatology” Testing for various autoantibodies in Indian children with lupus can help predict disease symptoms and risks.
1 citations
,
March 2019 in “Journal of Interdisciplinary Medicine” A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.
10 citations
,
March 2014 in “Scandinavian journal of clinical and laboratory investigation” Malondialdehyde-modified DNA may trigger an immune response in alopecia areata patients.
1 citations
,
August 2023 in “JAMA Dermatology” Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.